- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07574489
Whole Versus Partial Gland Boost During Prostate SBRT
Whole Versus Partial Gland Boost During Prostate SBRT (Gland Boost)
The purpose of this randomized phase II trial is to compare dose escalation of the prostate versus the dominant intra-prostatic lesion in a reduced fraction radiation therapy regimen.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
This is a phase 2 randomized clinical trial evaluating two dose escalation strategies during prostate stereotactic body radiotherapy (SBRT). A total of 160 patients with prostate adenocarcinoma will be enrolled and randomized in a 1:1 ratio to one of two treatment arms.
160 patients will be enrolled in this study over 3.2 years. Eligible participants will be stratified by risk group and tamsulosin use and randomized to one of two treatment arms. Both arms will receive 3625 cGy to the prostate plus planning margin delivered over 5 fractions. Arm A will receive an additional boost of 4000 cGy to the prostate alone. Arm B will receive an additional boost of 4500 cGy to the dominant intra-prostatic lesion (DIL). Acute and chronic GU and GI toxicities will be measured, as well as biochemical progression-free survival. Toxicities will be measured using CTCAE, Radiation Therapy Oncology Group, and Expanded Prostate Cancer Index Composite domains.
Participants will be followed for up to 5 years after completion of treatment.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Krishna Gottipati, MS
- Telefonnummer: 4025593518
- E-post: krgottipati@unmc.edu
Studera Kontakt Backup
- Namn: IIT Office Gottipati
- Telefonnummer: 4025590963
- E-post: IITOFFICE@unmc.edu
Studieorter
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna, 68198
- Fred & Pamela Buffet Cancer Center
-
Kontakt:
- Michael Baine, MD, PhD
- Telefonnummer: (402) 552-2703
- E-post: mbaine@unmc.edu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Adults ≥19 years of age
- Patients with a diagnosis of prostate adenocarcinoma for whom SBRT to the prostate +/- proximal seminal vesicles is being offered
- Prostate gland volume less than 100 cc prior to initiation of ADT as reported at time of biopsy or by separate measure with ultrasound or other imaging modalities, including MRI or CT scan
- PI-RADS 4 or 5 lesion seen on pretreatment MRI
- IPSS/AUA (Appendix D, E) symptom score less than 16
Exclusion Criteria:
- Prior treatment for prostate cancer
- Prior solid cancer diagnosis in the last 5 years
- Any history of anal or rectal cancer
- Any history of invasive carcinoma of the bladder
- History of prior circumferential resection of the rectum (such as LAR or APR)
- History of inflammatory bowel syndromes not adequately controlled on current medication regimen
- Urinary or fecal incontinence or chronic diarrhea requiring more than 1 pad per day
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Arm A: boost to prostate alone
Participants assigned to Arm A will receive external beam radiation therapy consisting of 3625 cGy to the planning target volume (PTV), plus a boost of 4000 cGy to the clinical target volume (CTV), consisting of the prostate alone without a margin. Treatment will be delivered over 5 fractions with at least 36 hours between fractions via simultaneous integrated boost (SIB). |
External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost |
|
Experimentell: Arm B: boost to dominant intra-prostatic lesion (DIL)
Participants assigned to Arm B will receive external beam radiation therapy consisting of 3625 cGy to the planning target volume (PTV), plus a boost of 4500 cGy to the dominant intra-prostatic lesion (DIL). Treatment will be delivered over 5 fractions with at least 36 hours between fractions via simultaneous integrated boost (SIB). |
External beam radiation therapy delivered via linear accelerator-based SBRT using simultaneous integrated boost to the dominant intra-prostatic lesion. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Grade 2 or Higher Acute Genitourinary Toxicity
Tidsram: From end of treatment to 3 months post-treatment
|
To evaluate acute genitourinary (GU) toxicities grade 2 or higher by cumulative incidence from the end of treatment to 3 months post-treatment using Common Terminology Criteria for Adverse Events Version 6.0 (CTCAE) |
From end of treatment to 3 months post-treatment
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Grade 2 or Higher Acute Gastrointestinal Toxicity
Tidsram: From end of treatment to 3 months post-treatment
|
To evaluate gastrointestinal (GI) toxicities grade 2 or higher by cumulative incidence from the end of treatment to 3 months post-treatment using CTCAE |
From end of treatment to 3 months post-treatment
|
|
Biochemical Progression-Free Survival
Tidsram: From initiation of study treatment to 5 years post-treatment
|
Time from initiation of study treatment to biochemical disease progression or death from any cause |
From initiation of study treatment to 5 years post-treatment
|
|
Chronic Gastrointestinal Toxicity - Cumulative Incidence
Tidsram: From 6 months to 21 months post-treatment
|
Cumulative incidence of chronic gastrointestinal (GI) toxicities assessed using CTCAE, Radiation Therapy Oncology Group (RTOG), and Expanded Prostate Cancer Index Composite (EPIC) domains. |
From 6 months to 21 months post-treatment
|
|
Chronic Genitourinary Toxicity - Cumulative Incidence
Tidsram: From 6 months to 21 months post-treatment
|
Cumulative incidence of chronic genitourinary (GU) toxicities assessed using CTCAE, RTOG, and EPIC domains. |
From 6 months to 21 months post-treatment
|
|
Chronic Gastrointestinal Toxicity
Tidsram: At 5 years
|
To evaluate chronic GI toxicities at 5 years using CTCAE, RTOG, and EPIC domains. |
At 5 years
|
|
Chronic Genitourinary Toxicity
Tidsram: At 5 years
|
To evaluate chronic GU toxicities at 5 years using CTCAE, RTOG, and EPIC domains. |
At 5 years
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Michael Baine, MD, PhD, University of Nebraska medicine
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- Gland Boost
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .